Only peer-reviewed, indexed publications were considered
Physiol Behav 104(5):816822
Among more than 293,000 participants , the estimated one-year risk of developing NAION was 0.04% among GLP-1 receptor agonist users compared with 0.02% among SGLT-2 inhibitor users
24500, Thermo Fisher (CSIRO)), SnakeSkin dialysis tubing 10 kDa (88243, Thermo Fisher Scientific), bovine serum albumin (A7906, Merck), formaldehyde solution 37% (F1635, Merck), sodium bicarbonate (S6014, Merck), sodium carbonate (anhydrous) (PHR1948, Merck), scintillation fluid (Ultima Gold 2x, 6013329, PerkinElmer), 30% H 2 O 2 (18312, Merck), solvable solution (6NE9100, PerkinElmer), liquid scintillation vials glass (986541, Merck), ( 3 H)-oleic acid (O-1518, Merck), 14 C-INS human (ARC-3146, Bio Scientific), insulin human recombinant (91077C, SAFC), Accu-Chek Performa strips (p-4015630981946, Amcal), Accu-Chek Performa blood glucose meter kit (p-4015630982219, Amcal), STZ (AG-CN2-0046-G001, Sapphire Biosciences), cellulase, enzyme blend (SAE0020, Merck), -glucosidase from almonds (G4511, Merck), Hoechst 33342 (14533, Merck), Alexa Fluor 488 TFP ester (A37570, Thermo Fisher), TEM grids (71150, Electron Microscopy Sciences), RPMI-1640 (Merck), Percoll (Merck), penicillinstreptomycin (Merck) and foetal calf serum (Merck)
Catherino WH, Jeng MH, Jordan VC
Sproat R
